Clinical trials: Overactive Bladder Syndrome
Overactive Bladder
Safety Study of hMaxi-K Gene Transfer to Treat Overactive Bladder and Detrusor Overactivity
The purpose of this study is to evaluate the safety of a new product that uses human gene transfer (called hMaxi-K) when it is given to patients with overactive bladder.
- Trial name
- NCT00495053
- Testing
- hMaxi-K
- Where
- United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Urovant Sciences GmbH
Overactive Bladder, Urinary Urge Incontinence
InterStim Basic Evaluation Lead Post-Market Clinical Follow-up Study
Post-market clinical follow-up for continued assessment of safety and performance of the InterStim basic evaluation lead and foramen needle(s) used during a therapy evaluation.
- Conditions
- Overactive Bladder, Urinary Urge Incontinence, Urgency-frequency Syndrome
- Trial name
- BASIC (NCT04016324)
- Testing
- InterStim Basic Evaluation lead and foramen needle
- Where
- 15 sites in United States, Canada and 2 more
- Volunteers
- 110 people
- Sponsor
- MedtronicNeuro
Overactive Bladder Syndrome
A Multicenter Trial to Investigate Fesoterodine Sustained Release in Overactive Bladder Syndrome
The trial consisted of a 2 week Run-In period, 12 week double-blind Treatment period and 2 week Safety Follow-Up period. Subjects were randomized to one of 4 treatment arms receiving either fesoterodine (SPM 907) 4mg…
- Trial name
- NCT00220363
- Testing
- SPM 907
- Where
- Germany
- Sponsor
- Pfizer
Overactive Bladder (OAB)
Tensi+ for Treating Overactive Bladder
The purpose of the study is to evaluate the safety and effectiveness of the Tensi+ device using Transcutaneous Posterior Tibial Nerve Stimulation (TPTNS) for treating patients suffering from OAB symptoms urinary frequency…
- Trial name
- NCT07300904
- Testing
- Tensi+
- Where
- 3 sites in United States, Canada
- Volunteers
- 60 people
- Sponsor
- Stimuli Technology
Overactive Bladder Syndrome
Long-Term Open-Label Extension Trial for Subjects Completing the Phase 3 Trial of Fesoterodine (SP584) for the Treatment of Overactive Bladder Syndrome
This trial will provide long-term data on safety, satisfaction and maintenance on therapy of fesoterodine (SPM 907) in subjects with overactive bladder syndrome.
- Trial name
- NCT00220376
- Testing
- SPM 907
- Where
- United States
- Sponsor
- Pfizer
BPH, BPH With Urinary Obstruction With Other Lower Urinary Tract Symptoms
BE Technologies Mobile Uroflowmetry Validation Study
This research study is studying MenHealth Mobile Uroflowmetry as a diagnostic tool for LUTS (lower urinary tract symptoms), a group of conditions involving the bladder, urinary sphincter, urethra and the prostate.
- Conditions
- BPH, BPH With Urinary Obstruction With Other Lower Urinary Tract Symptoms, BPH Without Urinary Obstruction, BPH Without Urinary Obstruction With Other Lower Urinary Tract Symptoms
- Trial name
- NCT04599283
- Testing
- MenHealth Uroflowmeter
- Where
- United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- BE Technologies Inc
Overactive Bladder Syndrome
Transvaginal Detrusor Nerve Radiofrequency Ablation for Treatment of Overactive Bladder
The goal of this Safety and efficacy of transvaginal Detrusor Nerve Ablation for treatment of overactive bladder symptoms, including refractory overactive bladder The main questions it aims to answer are: •Change from baseline to…
- Trial name
- NCT06283498
- Testing
- Device Morpheus8V
- Where
- 3 sites in United States, Colombia
- Volunteers
- 32 people
- Sponsor
- InMode MD Ltd.
Overactive Bladder Syndrome
Long-Term Open-Label Extension Trial for Subjects Completing the Phase 3 Trial of Fesoterodine (SP583) for the Treatment of Overactive Bladder Syndrome
This trial will provide long-term data on safety, satisfaction and maintenance on therapy of fesoterodine (SPM 907) in subjects with overactive bladder syndrome.
- Trial name
- NCT00220402
- Testing
- SPM 907
- Where
- Germany
- Sponsor
- Pfizer